Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys (TIGRE)

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: May 1, 2006
Last updated: February 22, 2017
Last verified: February 2017
The purpose of this study is to explore the safety and efficacy of two different immunosuppressive regimens (sequential tacrolimus/mycophenolate mofetil [MMF] plus steroids versus tacrolimus plus MMF, following induction with daclizumab) in recipients of marginal donor kidneys.

Condition Intervention Phase
Drug: tacrolimus
Drug: mycophenolate mofetil
Drug: steroids
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open, Multicentre, Randomised, Parallel Group Study to Compare in Marginal Old-for-old Renal Transplant Patients the Safety and Efficacy of Two Treatments: Sequential Mycophenolate Mofetil/Delayed Tacrolimus Plus Steroids vs Tacrolimus Plus Mycophenolate Mofetil in Patients Requiring Induction With Anti-IL2 Antibody

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Calculated creatinine clearance [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Acute Rejection, patient survival, graft survival [ Time Frame: 6 months ]

Enrollment: 142
Study Start Date: September 2004
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: tacrolimus
Other Names:
  • Prograf
  • FK506
Drug: mycophenolate mofetil
Other Name: MMF
Experimental: 2
Drug: tacrolimus
Other Names:
  • Prograf
  • FK506
Drug: mycophenolate mofetil
Other Name: MMF
Drug: steroids

Detailed Description:

An open, multicentre, randomized, parallel group study to compare in marginal old-for-old renal transplant patients the safety and efficacy of two treatments: sequential mycophenolate mofetil/delayed tacrolimus plus steroids vs tacrolimus plus mycophenolate mofetil, in patients requiring induction with anti-IL2 monoclonal antibody.

Elderly (≥50 years) low risk patients (PRA grade ≤50%, in the previous 6 months) receiving an allograft transplantation of marginal kidney(s) from elderly (>65 years) donors (old-for-old allocation) will be randomized to one of the following treatment arms:

Arm1: Sequential mycophenolate mofetil/tacrolimus/steroids

Arm2: Tacrolimus/mycophenolate mofetil/steroid one single dose (perioperatively)


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients minimum 60 years of age undergoing a cadaveric kidney transplant
  • Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation.
  • Donors older than 60 years
  • Female patients of child bearing age agree to practice effective birth control during the study.
  • Patient has been fully informed and has given written informed consent

Exclusion Criteria:

  • Patient has significant, uncontrolled, concomitant infections and/or severe diarrhoea, vomiting, or active peptic ulcer
  • Patient has previously received or is receiving an organ transplant other than kidney or a kidney retransplant
  • Any pathology or medical condition that can interfere with this protocol study proposal
  • Other exclusion criteria apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00321113

Bologna, Italy, 40138
Cagliari, Italy, 09134
Milano, Italy, 30100
Modena, Italy, 41100
Padova, Italy, 35128
Palermo, Italy, 90127
Roma, Italy, 00144
Roma, Italy, 00161
Roma, Italy, 00168
Sassari, Italy, 35128
Siena, Italy, 53100
Treviso, Italy
Udine, Italy
Vicenza, Italy, 36100
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Europe B.V.
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00321113     History of Changes
Other Study ID Numbers: FG-506-02-IT-01
Study First Received: May 1, 2006
Last Updated: February 22, 2017

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on April 28, 2017